Patent ductus arteriosus (PDA) remains a prominent clinical challenge in the management of preterm infants. During fetal life, the ductus arteriosus diverts blood away from the underdeveloped lungs, ...

Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.

In light of the variability in early ductal constriction and the early hemodynamic impact of an unconstricted DA, it may be that closure after the first 24 hours of life may be too late. Further, the ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published a new position statement that provides best-practice guidance for the treatment of patent ductus arteriosus (PDA) using ...

Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...

“This position statement represents a collective effort between neonatology, anesthesia, and interventional cardiology to provide comprehensive guidance on tcPDA device occlusion that can be adapted ...

Sailesh Kotecha's family settled in London after being expelled from Uganda in 1972. Given his strong interest in human biology, he opted to study medicine. He was awarded a scholarship to study at ...

Pediatric experts from Le Bonheur’s Heart Institute and the University of Tennessee Health Science Center will present lectures, posters, abstracts and hands-on workshops. Pediatric experts from Le ...

Larger DA diameter was significantly related to this low systemic blood flow in the early hours after birth. [13] By the time the PDA became clinically apparent (mean 72 hours), the infants were ...